Mexiletine in the prophylaxis of ventricular arrhythmias during acute myocardial infarction

Ronald W F Campbell, Stephen C Achuff, Anthony Pottage, Alan Murray, Laurence F. Prescott, Desmond G. Julian

Research output: Contribution to journalArticle

Abstract

In a double-blind study involving 165 patients we examined the role of mexiletine, a new antiarrhythmic drug, for the prophylaxis of ventricular arrhythmias after acute myocardial infarction. Mexiletine or placebo was given orally to patients on arrival in the coronary care unit, and continuous electrocardiographic tape recordings were used to document arrhythmias. Ventricular tachycardia and R-on-T ventricular ectopic beats were significantly reduced in the mexiletine patients, but too few episodes of ventricular fibrillation occurred for statistical comment. When arrhythmias did occur in the mexiletine group, it was usually early in the study, at which time plasma drug levels were low. Adverse effects were uncommon. Patients who were given therapy, but in whom acute myocardial infarction could not be confirmed, suffered no serious consequences of taking mexiletine. The results demonstrate the benefit and limitations of prophylactic oral antiarrhythmic therapy for patients with acute myocardial infarction.

Original languageEnglish (US)
Pages (from-to)43-52
Number of pages10
JournalJournal of Cardiovascular Pharmacology
Volume1
Issue number1
StatePublished - 1979

Fingerprint

Mexiletine
Cardiac Arrhythmias
Myocardial Infarction
Tape Recording
Coronary Care Units
Ventricular Premature Complexes
Anti-Arrhythmia Agents
Ventricular Fibrillation
Ventricular Tachycardia
Double-Blind Method
Placebos
Therapeutics
Pharmaceutical Preparations

Keywords

  • Arrhythmias
  • Mexiletine
  • Myocardial infarction
  • Prophylaxis

ASJC Scopus subject areas

  • Cardiology and Cardiovascular Medicine
  • Pharmacology

Cite this

Campbell, R. W. F., Achuff, S. C., Pottage, A., Murray, A., Prescott, L. F., & Julian, D. G. (1979). Mexiletine in the prophylaxis of ventricular arrhythmias during acute myocardial infarction. Journal of Cardiovascular Pharmacology, 1(1), 43-52.

Mexiletine in the prophylaxis of ventricular arrhythmias during acute myocardial infarction. / Campbell, Ronald W F; Achuff, Stephen C; Pottage, Anthony; Murray, Alan; Prescott, Laurence F.; Julian, Desmond G.

In: Journal of Cardiovascular Pharmacology, Vol. 1, No. 1, 1979, p. 43-52.

Research output: Contribution to journalArticle

Campbell, RWF, Achuff, SC, Pottage, A, Murray, A, Prescott, LF & Julian, DG 1979, 'Mexiletine in the prophylaxis of ventricular arrhythmias during acute myocardial infarction', Journal of Cardiovascular Pharmacology, vol. 1, no. 1, pp. 43-52.
Campbell, Ronald W F ; Achuff, Stephen C ; Pottage, Anthony ; Murray, Alan ; Prescott, Laurence F. ; Julian, Desmond G. / Mexiletine in the prophylaxis of ventricular arrhythmias during acute myocardial infarction. In: Journal of Cardiovascular Pharmacology. 1979 ; Vol. 1, No. 1. pp. 43-52.
@article{972d0a9e3ba9486ba4d63b2e53bdeaaa,
title = "Mexiletine in the prophylaxis of ventricular arrhythmias during acute myocardial infarction",
abstract = "In a double-blind study involving 165 patients we examined the role of mexiletine, a new antiarrhythmic drug, for the prophylaxis of ventricular arrhythmias after acute myocardial infarction. Mexiletine or placebo was given orally to patients on arrival in the coronary care unit, and continuous electrocardiographic tape recordings were used to document arrhythmias. Ventricular tachycardia and R-on-T ventricular ectopic beats were significantly reduced in the mexiletine patients, but too few episodes of ventricular fibrillation occurred for statistical comment. When arrhythmias did occur in the mexiletine group, it was usually early in the study, at which time plasma drug levels were low. Adverse effects were uncommon. Patients who were given therapy, but in whom acute myocardial infarction could not be confirmed, suffered no serious consequences of taking mexiletine. The results demonstrate the benefit and limitations of prophylactic oral antiarrhythmic therapy for patients with acute myocardial infarction.",
keywords = "Arrhythmias, Mexiletine, Myocardial infarction, Prophylaxis",
author = "Campbell, {Ronald W F} and Achuff, {Stephen C} and Anthony Pottage and Alan Murray and Prescott, {Laurence F.} and Julian, {Desmond G.}",
year = "1979",
language = "English (US)",
volume = "1",
pages = "43--52",
journal = "Journal of Cardiovascular Pharmacology",
issn = "0160-2446",
publisher = "Lippincott Williams and Wilkins",
number = "1",

}

TY - JOUR

T1 - Mexiletine in the prophylaxis of ventricular arrhythmias during acute myocardial infarction

AU - Campbell, Ronald W F

AU - Achuff, Stephen C

AU - Pottage, Anthony

AU - Murray, Alan

AU - Prescott, Laurence F.

AU - Julian, Desmond G.

PY - 1979

Y1 - 1979

N2 - In a double-blind study involving 165 patients we examined the role of mexiletine, a new antiarrhythmic drug, for the prophylaxis of ventricular arrhythmias after acute myocardial infarction. Mexiletine or placebo was given orally to patients on arrival in the coronary care unit, and continuous electrocardiographic tape recordings were used to document arrhythmias. Ventricular tachycardia and R-on-T ventricular ectopic beats were significantly reduced in the mexiletine patients, but too few episodes of ventricular fibrillation occurred for statistical comment. When arrhythmias did occur in the mexiletine group, it was usually early in the study, at which time plasma drug levels were low. Adverse effects were uncommon. Patients who were given therapy, but in whom acute myocardial infarction could not be confirmed, suffered no serious consequences of taking mexiletine. The results demonstrate the benefit and limitations of prophylactic oral antiarrhythmic therapy for patients with acute myocardial infarction.

AB - In a double-blind study involving 165 patients we examined the role of mexiletine, a new antiarrhythmic drug, for the prophylaxis of ventricular arrhythmias after acute myocardial infarction. Mexiletine or placebo was given orally to patients on arrival in the coronary care unit, and continuous electrocardiographic tape recordings were used to document arrhythmias. Ventricular tachycardia and R-on-T ventricular ectopic beats were significantly reduced in the mexiletine patients, but too few episodes of ventricular fibrillation occurred for statistical comment. When arrhythmias did occur in the mexiletine group, it was usually early in the study, at which time plasma drug levels were low. Adverse effects were uncommon. Patients who were given therapy, but in whom acute myocardial infarction could not be confirmed, suffered no serious consequences of taking mexiletine. The results demonstrate the benefit and limitations of prophylactic oral antiarrhythmic therapy for patients with acute myocardial infarction.

KW - Arrhythmias

KW - Mexiletine

KW - Myocardial infarction

KW - Prophylaxis

UR - http://www.scopus.com/inward/record.url?scp=0018666475&partnerID=8YFLogxK

UR - http://www.scopus.com/inward/citedby.url?scp=0018666475&partnerID=8YFLogxK

M3 - Article

VL - 1

SP - 43

EP - 52

JO - Journal of Cardiovascular Pharmacology

JF - Journal of Cardiovascular Pharmacology

SN - 0160-2446

IS - 1

ER -